Predicting ovarian activity in women affected by early breast cancer: Ameta-analysis-based nomogram

Agnese Barnabei, Lidia Strigari, Paolo Marchetti, Valentina Sini, Liana De Vecchis, Salvatore Maria Corsello, Francesco Torino

Research output: Contribution to journalArticlepeer-review


Background. The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients. Materials and Methods. To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms “amenorrhea/chemically induced,” “ovarian reserve,” “anti-Mullerian hormone/blood,” and “breast neoplasms/drug therapy.” Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model. Results. The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602–0.904) compared with those older than 40 years (0.678; 95% CI: 0.491–0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy. Conclusion. After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures.

Original languageEnglish
Pages (from-to)1111-1118
Number of pages8
JournalThe oncologist
Issue number10
Publication statusPublished - Sep 4 2015


  • Anti-Müllerian hormone
  • Breast cancer
  • Ovarian reserve
  • Ovarian toxicity
  • Predictive factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Predicting ovarian activity in women affected by early breast cancer: Ameta-analysis-based nomogram'. Together they form a unique fingerprint.

Cite this